Johnson & Johnson vaccine is expected to be approved in February
–
[AFP=연합뉴스 자료사진]
–
(New York = Yonhap News) Correspondent Kang Gun-taek = Donald Trump The chief executive of the U.S. administration’s new coronavirus infection (Corona 19) vaccine development program,’Ultra-Fast Operation’, delayed the expected timing of approval of the UK AstraZeneca Corona 19 vaccine.
“If everything goes well (in the US), emergency use will probably be approved in April,” said Montsef Slawi, chief executive of the High Speed Operations Team, regarding the AstraZeneca vaccine, which was approved for emergency use by the British government on the 30th (local time). I expect,” reported Reuters.
This is a delay of at least two months from the US government’s existing timetable, according to the US political media Politico. Earlier this month, Slawi predicted that AstraZeneca would apply for emergency use to the US Food and Drug Administration (FDA) as early as February next year.
Chief Executive Officer Slawi met with reporters that day and added that 29,000 people were enrolled in AstraZeneca’s large-scale phase 3 clinical trial in the United States, and the recruitment of participants was almost finished.
Politico analyzed that the U.S. government’s delay in the estimated timing of the emergency use of the AstraZeneca vaccine was due to questions surrounding the effectiveness of the vaccine.
–
[로이터=연합뉴스 자료사진]
–
This vaccine, developed jointly by Oxford University and AstraZeneca, reaches 90% of the preventive effect if half of the dose is first inoculated and one additional dose is completely added a month later. Participants in some trials were given only half of the first dose due to the researchers’ mistake.
However, as with other vaccines, when the entire dose was normally administered twice, the preventive effect fell to 62%.
The average prevention rate is 70.4%, which is lower than that of Pfizer-Bioentech (95%) and Modena (94.5%).
In this regard, Slawy said, “It is important to note that one vaccine for Americans has a 95% prevention rate, while the other vaccine has a’X%’ (unknown).” “The sum of different clinical trials with different schedules and different materials. “I need a specific and clear number,” he said.
He also pointed out that the preventive effectiveness of the AstraZeneca vaccine in older people was “virtually little known.” This is because the elderly rarely participated in the existing clinical trials.
The US government has ordered 300 million doses of the AstraZeneca vaccine.
On the other hand, regarding the COVID-19 vaccine that Johnson & Johnson is developing, “it can become a game changer,” said Slawy, who said, “This vaccine will have the same preventive effect as Moder or Pfizer vaccines with only one dose.” Praised it.
He said that the recruitment of the Johnson & Johnson phase 3 test participants was over, and he predicted that the application for emergency use in January of next year will be approved in February.
<저작권자(c) 연합뉴스,
Unauthorized reproduction-redistribution prohibited>
2020/12/31 07:45 sent
–
